Clinical Trial Detail

NCT ID NCT02412371
Title A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors AbbVie
Indications

lung non-small cell carcinoma

Therapies

Veliparib

Carboplatin + Paclitaxel

Age Groups: adult

No variant requirements are available.